Table 2.
Protection against any symptomatic COVID-19 disease by the receipt of complete regimens of vaccines *.
| Cases | Matched Controls | Protective Effectiveness (PE) % (95% Confidence Interval (CI)) | ||||||
|---|---|---|---|---|---|---|---|---|
| Vaccines | Vaccinees | Non-Vaccinees | Vaccinees | Non-Vaccinees | Crude PE | p-Value | Adjusted † PE | p-Value |
| Any vaccine ‡ | 155 | 158 | 564 | 632 | −8 (−44, 19) | 0.589 | 12 (−21, 37) ƭ | 0.423 |
| Serum Institute of India (ChAdOx1 nCoV-19) § | 105 | 156 | 179 | 484 | −79 (−156, −26) | 0.001 | −45 (−119, 4) ƭ | 0.078 |
| Sinopharm (Vero Cell-Inactivated) || | 35 | 153 | 100 | 396 | 23 (−28, 54) | 0.309 | 29 (−22, 58) Ƭ | 0.213 |
| Moderna (mRNA-1273) ¶ | 6 | 150 | 42 | 357 | 69 (25, 87) | 0.010 | 64 (10,86) ƾ | 0.029 |
* Received a second dose of vaccine at least 14 days before presentation. † Adjusted by forced variable (severity at presentation) with other covariates significantly associated at p < 0.05 in the stepwise model: ƭ study month, gender, religion, household size, and household income. Ƭ Body mass index and smoking status. ƾ Gender and smoking status. ‡ Any vaccine (Serum Institute of India (ChAdOx1 nCoV-19), Sinopharm (Vero Cell-Inactivated), Moderna (mRNA-1273), Pfizer-BioNTech (BNT162b2), and Sinovac (Vero Cell-Inactivated). § Participants with only Serum Institute of India-ChAdOx1 nCoV-19 vaccination or non-vaccinees (cases = 270; matched controls = 663); 9 cases were excluded since no matched controls were available. || Participants with only Sinopharm (Vero Cell-Inactivated) vaccination or non-vaccines (cases = 194; matched controls = 496); 6 cases excluded since no matched controls were available. ¶ Participants with only Moderna mRNA-1273 vaccination or non-vaccinees (cases = 165; matched controls = 399); 9 cases excluded since no matched controls were available.